213 results on '"Singal, Amit G."'
Search Results
2. Systemic Therapies for Hepatocellular Carcinoma in India
3. Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours
4. A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma
5. Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: A systematic review and individual patient data meta-analysis
6. Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma
7. Blood-based biomarkers for hepatocellular carcinoma screening: Approaching the end of the ultrasound era?
8. Rational HCC screening approaches for patients with NAFLD
9. Reply to: “Correction for length bias reduces the mortality benefit from hepatocellular carcinoma surveillance”
10. Prevention of Hepatocellular Carcinoma (HCC). White Paper of the Texas Collaborative Center for Hepatocellular Cancer (TeCH) Multi-stakeholder Conference.
11. Breakthroughs in Hepatocellular Carcinoma Therapies.
12. International Liver Cancer Association (ILCA) white paper on hepatocellular carcinoma risk stratification and surveillance.
13. INASL Consensus on Management of HCC: Navigating an Evolving Field
14. Reply.
15. PNPLA3, Obesity, and Heavy Alcohol Use in Cirrhosis Patients May Exert a Synergistic Increase Hepatocellular Carcinoma Risk.
16. PKD1 mutant clones within cirrhotic livers inhibit steatohepatitis without promoting cancer.
17. Characterization of Prevalent, Post-Endoscopy, and Incident Esophageal Cancer in the United States: A Large Retrospective Cohort Study.
18. HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: A meta-analysis.
19. Prevalence of Forceps Polypectomy of Nondiminutive Polyps Is Substantial But Modifiable.
20. Cachexia is Prevalent in Patients With Hepatocellular Carcinoma and Associated With Worse Prognosis.
21. A Blood-Based Prognostic Liver Secretome Signature Predicts Long-term Risk of Hepatic Decompensation in Cirrhosis.
22. Molecular Signature Predictive of Long-Term Liver Fibrosis Progression to Inform Antifibrotic Drug Development.
23. Tu1555 IMMUNOTHERAPY VERSUS LENVATINIB IN ADVANCED HEPATOCELLULAR CARCINOMA: A MULTICENTER, NATIONWIDE PROPENSITY SCORE MATCHING ANALYSIS.
24. Tu1559 RISK OF HEPATOCELLULAR CARCINOMA AMONGST SUBCENTIMETER NODULES ON SURVEILLANCE ULTRASOUND: A SYSTEMATIC REVIEW.
25. Tu1540 SOCIODEMOGRAPHIC FACTORS EXACERBATE EXISTING DISPARITIES IN TUMOR STAGE AT DIAGNOSIS AMONG ETHNIC MINORITIES WITH HEPATOCELLULAR CARCINOMA.
26. Tu1544 CLINICAL BENEFITS OF HEPATOCELLULAR CARCINOMA SURVEILLANCE IN A CONTEMPORARY COHORT OF AT-RISK PATIENTS.
27. Tu1534 MULTICENTER COMPARISON OF ABBREVIATED MRI VERSUS ULTRASOUND FOR DETECTING EARLY-STAGE HEPATOCELLULAR CARCINOMA IN PATIENTS WITH CIRRHOSIS.
28. Sa1550 PATIENT PORTAL USE IN CIRRHOSIS IS ASSOCIATED WITH PATIENT AGE AND HEPATIC DECOMPENSATION.
29. Sa1549 PATIENTS WITH CIRRHOSIS VIEW AMBULATORY HCC SCREENING RESULTS MORE RAPIDLY THAN PROVIDERS, ESPECIALLY YOUNGER AND WHITE PATIENTS.
30. Mo1477 DEVELOPMENT AND VALIDATION OF CASE-FINDING ALGORITHMS TO IDENTIFY CHOLANGIOCARCINOMA AND ITS SUBTYPES IN VETERANS HEALTH ADMINISTRATION DATA.
31. Su1170 EXAM QUALITY OF LIVER ULTRASOUND AND DYNAMIC CONTRAST-ENHANCED MRI AND IMPACT ON EARLY-STAGE HCC DETECTION IN PATIENTS WITH CIRRHOSIS.
32. Su1168 SERUM LEVELS OF TOTAL BILE ACIDS ARE ASSOCIATED WITH AN INCREASED RISK OF HEPATOCELLULAR CARCINOMA IN PATIENTS WITH CIRRHOSIS. A PROSPECTIVE COHORT STUDY.
33. 1090 RISK PREDICTION FOR COLORECTAL CANCER USING QUANTITATIVE FECAL IMMUNOCHEMICAL TEST RESULTS — A STATISTICAL SOLUTION TO THE COLONOSCOPY CAPACITY ISSUE.
34. 1251 SERUM BIOMARKER SIGNATURE IS PREDICTIVE OF THE RISK OF HEPATOCELLULAR CANCER IN PATIENTS WITH CIRRHOSIS.
35. 565 A PROSPECTIVE STUDY OF ANTIBIOTIC USE IN CHILDHOOD AND RISK OF ADULT-ONSET COLORECTAL CANCER.
36. 186 IMPACT OF CENSUS TRACT-BASED SOCIOECONOMIC STATUS ON TRENDS OF COLORECTAL CANCER INCIDENCE DIFFERED BY RACE AND ETHNICITY.
37. Financial Burden of Hepatocellular Carcinoma Screening in Patients With Cirrhosis.
38. Racial and Ethnic Disparities in Survival Among Patients With Hepatocellular Carcinoma in the United States: A Systematic Review and Meta-Analysis.
39. Rational HCC screening approaches for patients with NAFLD.
40. Conceptual Model for the Hepatocellular Carcinoma Screening Continuum: Current Status and Research Agenda.
41. Provider Attitudes Toward Risk-Based Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis in the United States.
42. Reply.
43. Surveillance and Monitoring of Hepatocellular Carcinoma During the COVID-19 Pandemic.
44. Hepatocellular Carcinoma Surveillance Patterns and Outcomes in Patients With Cirrhosis.
45. Incidence of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease.
46. A Conceptual Model for Implementation and Evaluation of Interventions Across the Hepatocellular Carcinoma Care Continuum.
47. The quest for precision oncology with immune checkpoint inhibitors for hepatocellular carcinoma.
48. Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis.
49. Epidemiology and surveillance for hepatocellular carcinoma: New trends.
50. Risk Stratification Model for Hepatocellular Cancer in Patients With Cirrhosis.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.